Sign inCreate account

Report workspace tools

NCT05389462TERMINATEDanonymous

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors

Sponsor

Source record

ADC Therapeutics S.A.

Phase

Source record

Phase 1b

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Mipasetamab Uzoptirine (ADCT-601)

Indication / condition

AI-normalized

Advanced Solid Tumors

Intervention

Source record

ADCT-601, Gemcitabine

Source & freshness

Source record

NCT ID

NCT05389462

Original source

ClinicalTrials.gov

Source last updated

May 22, 2025

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05389462

Title

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors

Sponsor

ADC Therapeutics S.A.

Status

TERMINATED

Phase

Phase 1b

Condition raw

Advanced Solid Tumors

Condition normalized

Advanced Solid Tumors

Modality raw

Advanced Solid Tumors

Modality normalized

monoclonal antibody

Target raw

Mipasetamab Uzoptirine (ADCT-601)

Target normalized

Mipasetamab Uzoptirine (ADCT-601)

Interventions

ADCT-601, Gemcitabine

Public preview

Source record

ADC Therapeutics S.A. initiated a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumors, particularly focusing on sarcomas and pancreatic cancer. The study aimed to establish the recommended phase 2 dose and assess the drug's efficacy in combination with gemcitabine.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05389462

Status

TERMINATED

Phase

Phase 1b

Sponsor

ADC Therapeutics S.A.

Executive brief

Investment-Ready Snapshot

ADC Therapeutics S.A. initiated a clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumors, particularly focusing on sarcomas and pancreatic cancer. The study aimed to establish the recommended phase 2 dose and assess the drug's efficacy in combination with gemcitabine.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 22, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05389462

Indication

Advanced Solid Tumors

Modality

monoclonal antibody

Target

Mipasetamab Uzoptirine (ADCT-601)

Intervention

ADCT-601, Gemcitabine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.